Zhang, M.-Q., Zheng, Y.-L., Chen, H., Tu, J.-F., Shen, Y., Guo, J.-P., Yang, X.-H., Yuan, S.-R., Chen, L.-Z., Chai, J.-J., Lu, J.-H. and Zhai, C.-L. (2013) Sodium Tanshinone IIA Sulfonate Protects Rat Myocardium against Ischemia-Reperfusion Injury via Activation of PI3K/Akt/FOXO3A/Bim Pathway. Acta Pharmacologia Sinica, 34, 1386-1396.
http://dx.doi.org/10.1038/aps.2013.91

has been cited by the following article:

• TITLE: Clinical Study of Sulfotanshinone Sodium Injection in Treating Non-Ischemic Retinal Vein Occlusion

  AUTHORS: Bingwen Lu, Xingwei Wu

  KEYWORDS: Sulfotanshinone Sodium Injection, Non-Ischemic Retinal Vein Occlusion

  JOURNAL NAME: Chinese Medicine, Vol.6 No.2, May 12, 2015

  ABSTRACT: Objectives: To study the effect of sulfotanshinone sodium (SS) injection in the treatment of non-ischemic retinal vein occlusion (RVO). Methods: Sixty-two RVO patients treated in our hospital between Jan. 2013 and Oct. 2014 were randomly divided into Control Group (30 patients; Bendazol tablets) and Treatment Group (32 patients, Bendazol tablets + SS injections), each with a follow-up period of 6 months. Statistical analysis was then performed on changes in visual acuity, central retinal thickness (CRT) and retinal circulation time (RCT) before and after the treatment. Results: After treatment, both Control Group and Treatment Group witnessed an improvement on visual acuity (Control Group: t = 2.103, p = 0.044; Treatment Group: t = 8.021, p = 0.000). Visual acuity could be greatly improved in Treatment Group when compared with Control Group, with significant differences (p